ARCHIVES

Clinical Cooperative Groups Asked To Develop Tamoxifen Prevention Trial; CGOPs To Participate

This article is from The Cancer Letter archive.

Vol. 16 No. 27 | July 6, 1990

Download PDF Visit The Full Archive

Related Articles

In Brief: Breast Cancer Projects To Pay For Concurrent Pathology Review; Laetrile Study Entry Closed

May 19, 1978

Caribbean Conference Reports Incidence Differences With U.S.

August 22, 1986

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

April 24, 1998

In Brief: Cancer Act renewal, Appropriations Bill Caught In Squeeze Between Conventions

August 1, 1980

In Brief: House Passes Bill Extending Saccharin Status To 1981; Execs No Enthusiastic Over New SES

August 3, 1979

In odd aftermath of FDA Commissioner Mark McClellan’s lecture, NCI Director Andrew von Eschenbach forwards the commissioner’s thank-you note to 3,000 NCI staff. The email blast follows FDA’s return of NCI’s gift to McClellan.

March 12, 2004